Smith MT - Search Results

1

Muralidharan A, Smith MT. Muralidharan A, et al. Among authors: smith mt. J Pharm Pharmacol. 2011 Nov;63(11):1387-400. doi: 10.1111/j.2042-7158.2011.01340.x. Epub 2011 Aug 19. J Pharm Pharmacol. 2011. PMID: 21988420 Review.

2

The excitatory behavioral and antianalgesic pharmacology of normorphine-3-glucuronide after intracerebroventricular administration to rats.

Smith GD, Smith MT. Smith GD, et al. Among authors: smith mt. J Pharmacol Exp Ther. 1998 Jun;285(3):1157-62. J Pharmacol Exp Ther. 1998. PMID: 9618418

3

Antinociception versus serum concentration relationships following acute administration of intravenous morphine in male and female Sprague-Dawley rats: differences between the tail flick and hot plate nociceptive tests.

South SM, Edwards SR, Smith MT. South SM, et al. Among authors: smith mt. Clin Exp Pharmacol Physiol. 2009 Jan;36(1):20-8. doi: 10.1111/j.1440-1681.2008.05019.x. Epub 2008 Jul 29. Clin Exp Pharmacol Physiol. 2009. PMID: 18671713

4

Pharmacogenetics of pain and analgesia.

Smith MT, Muralidharan A. Smith MT, et al. Clin Genet. 2012 Oct;82(4):321-30. doi: 10.1111/j.1399-0004.2012.01936.x. Epub 2012 Aug 7. Clin Genet. 2012. PMID: 22779698 Review.

5

Small molecule angiotensin II type 2 receptor (AT₂R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats.

Smith MT, Wyse BD, Edwards SR. Smith MT, et al. Pain Med. 2013 May;14(5):692-705. doi: 10.1111/pme.12063. Epub 2013 Mar 14. Pain Med. 2013. PMID: 23489258

6

Optimization and characterization of a rat model of prostate cancer-induced bone pain using behavioral, pharmacological, radiological, histological and immunohistochemical methods.

Muralidharan A, Wyse BD, Smith MT. Muralidharan A, et al. Among authors: smith mt. Pharmacol Biochem Behav. 2013 May;106:33-46. doi: 10.1016/j.pbb.2013.02.020. Epub 2013 Mar 13. Pharmacol Biochem Behav. 2013. PMID: 23500189

7

A small molecule angiotensin II type 2 receptor (AT₂R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen-activated protein kinase (MAPK) and p44/p42 MAPK activation in the dorsal root ganglia.

Smith MT, Woodruff TM, Wyse BD, Muralidharan A, Walther T. Smith MT, et al. Pain Med. 2013 Oct;14(10):1557-68. doi: 10.1111/pme.12157. Epub 2013 Jun 6. Pain Med. 2013. PMID: 23742186 Free article.

8

Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.

Muralidharan A, Smith MT. Muralidharan A, et al. Among authors: smith mt. Inflammopharmacology. 2013 Oct;21(5):339-63. doi: 10.1007/s10787-013-0183-7. Epub 2013 Aug 6. Inflammopharmacology. 2013. PMID: 23918298 Free PMC article. Review.

9

Comment on "protective arms of the renin-angiotensin system in neurological disease".

Smith MT, Muralidharan A. Smith MT, et al. Clin Exp Pharmacol Physiol. 2013 Nov;40(11):838. doi: 10.1111/1440-1681.12169. Clin Exp Pharmacol Physiol. 2013. PMID: 24025036 No abstract available.

10

Analgesic efficacy and mode of action of a selective small molecule angiotensin II type 2 receptor antagonist in a rat model of prostate cancer-induced bone pain.

Muralidharan A, Wyse BD, Smith MT. Muralidharan A, et al. Among authors: smith mt. Pain Med. 2014 Jan;15(1):93-110. doi: 10.1111/pme.12258. Epub 2013 Oct 30. Pain Med. 2014. PMID: 24433468

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,090 results

Search Page